Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Robert Gould sold 15,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Fulcrum Therapeutics Trading Down 0.1%

FULC stock opened at $9.98 on Thursday. Fulcrum Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $15.74. The business’s 50-day moving average is $10.64 and its 200 day moving average is $8.72. The stock has a market cap of $540.12 million, a price-to-earnings ratio of -8.46 and a beta of 3.20.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, equities analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FULC. Adage Capital Partners GP L.L.C. boosted its position in shares of Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after purchasing an additional 1,589,000 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Fulcrum Therapeutics during the second quarter worth $9,207,000. Exome Asset Management LLC boosted its position in shares of Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after buying an additional 405,538 shares during the period. Invesco Ltd. grew its stake in shares of Fulcrum Therapeutics by 448.4% in the second quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock valued at $3,236,000 after buying an additional 384,566 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in shares of Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

FULC has been the subject of a number of recent research reports. Stifel Nicolaus set a $25.00 target price on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Piper Sandler reiterated an “overweight” rating and issued a $23.00 price objective (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Citigroup restated an “underperform” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Bank of America upped their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a research report on Tuesday, December 9th. Finally, Royal Bank Of Canada increased their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics presently has an average rating of “Hold” and an average price target of $19.00.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.